AOD 9604 Reconstitution and Dose Table

Published 2026-08-11 · Lyophile Editorial

AOD 9604 reconstitution calculator

Vial size (mg): 5 Diluent volume (mL): 2 Result: 2500 mcg/mL — 25 mcg per unit on a U-100 insulin syringe

Step-by-step math:

1. 5 mg × 1000 = 5000 mcg total peptide
2. 5000 mcg ÷ 2 mL = 2500 mcg/mL concentration
3. 2500 mcg/mL ÷ 100 units/mL = 25 mcg per unit
4. Target dose 250 mcg ÷ 2500 mcg/mL = 0.1 mL = 10 units

The general formula: (vial mg × 1000) ÷ (diluent mL) = mcg/mL. Divide any target dose by that concentration to get mL; multiply by 100 for U-100 syringe units.

This formula is the backbone of every peptide reconstitution calculation, and it fails in predictable ways when researchers skip units. A 5 mg vial is 5000 mcg — not 5 mcg, not 500 mcg. Mixing milligrams and micrograms in the same equation is the single most common arithmetic error in peptide research forums. Write the units out on paper before you touch a syringe. A single decimal slip turns a 250 mcg dose into 25 mcg — a tenfold underdose that silently invalidates an entire study arm.

The dilution ratio also determines whether your syringe markings are usable at all. A 5 mg vial reconstituted with 5 mL gives 1000 mcg/mL — 10 mcg per unit. A 250 mcg dose becomes 25 units. That is perfectly readable. The same vial with 1 mL gives 50 mcg per unit, where a 250 mcg dose is a 5-unit draw and a single misplaced line is a 50 mcg error. Choose your diluent volume based on the dose range you actually plan to administer, not on what is convenient to measure once.

How much bacteriostatic water for a 5 mg vial of AOD 9604?

Answer: 2 mL of bacteriostatic water yields 2500 mcg/mL — 25 mcg per unit on a U-100 insulin syringe. That's 20 doses of 250 mcg per vial.

The math: 5 mg = 5000 mcg. 5000 ÷ 2 = 2500 mcg/mL. Each 0.01 mL line on a U-100 syringe carries 25 mcg. A 250 mcg dose = 10 units. A 300 mcg dose = 12 units.

Why 2 mL instead of 1 mL? A 1 mL reconstitution gives 5000 mcg/mL — 50 mcg per unit. A 250 mcg dose becomes a 5-unit draw, where a half-unit overdraw is a 25 mcg error. The 2 mL dilution spreads the same dose across a larger, more readable volume and reduces peptide loss to vial walls and reconstitution dead-volume.

Dead-volume is the silent tax on every reconstitution. The needle hub holds roughly 0.02–0.05 mL that never reaches the vial, and the vial neck traps another 0.03–0.1 mL depending on its geometry. With 2 mL of diluent, that loss is 2.5–7.5% of the total preparation. With 0.5 mL, it is 10–30%. The smaller the reconstitution volume, the larger the proportional loss — and the more your actual delivered dose diverges from the label calculation. This is why 2 mL is the practical floor for a 5 mg vial; anything less and your "2500 mcg/mL" is fiction.

A second consideration is solubility kinetics. AOD 9604 is a 15-amino-acid peptide with a molecular weight of approximately 1813 Da — it dissolves readily in water, but it still needs surface area contact. A 1 mL bolus hitting a lyophilized cake can create a supersaturated microzone at the contact point, which slows dissolution and encourages aggregation. The 2 mL volume distributes the wetting front more evenly across the cake surface, reducing the time to full dissolution and the risk of localized peptide clumping.

AOD 9604 dose in syringe units (5 mg / 2 mL prep)

| Dose (mcg) | Volume (mL) | U-100 Syringe Units | |------------|-------------|---------------------| | 100 mcg | 0.04 mL | 4 units | | 150 mcg | 0.06 mL | 6 units | | 200 mcg | 0.08 mL | 8 units | | 250 mcg | 0.10 mL | 10 units | | 300 mcg | 0.12 mL | 12 units | | 500 mcg | 0.20 mL | 20 units |

A U-100 insulin syringe is marked in 100 units, each unit = 0.01 mL. That's the entire conversion: one unit is one hundredth of a milliliter. No ratio math needed.

Common failure mode: drawing from a vial reconstituted with 2 mL but losing ~0.05–0.1 mL to the vial neck and needle hub. Over 20 draws, that's a full dose lost. Most 5 mg vials have minimal overfill (5–10% per USP <1151>), so don't count on it to compensate. Draw with the vial inverted and the needle bevel fully submerged; withdraw slowly to minimize bubble retention.

Bubble retention is not cosmetic — it is volumetric error. A single 0.02 mL air bubble in the syringe barrel displaces 50 mcg of peptide at the 2500 mcg/mL concentration. That is 20% of a 250 mcg dose. Tap the barrel firmly after drawing to dislodge bubbles, then eject any air back into the vial before measuring your final dose. Never inject air into subcutaneous tissue; it is harmless in small volumes but it means you did not deliver what you measured.

Needle gauge matters more than most researchers expect. A 31-gauge insulin needle has an internal diameter of approximately 0.133 mm. Peptide solutions at 2500 mcg/mL are low-viscosity aqueous fluids, so they pass through fine needles without issue — but the draw itself is slower. A 29-gauge needle draws faster and is still fine for subcutaneous research injection. The tradeoff is injection-site trauma: smaller gauge numbers mean larger bores and more tissue disruption. For a 0.1 mL injection, the difference is negligible; for 0.2 mL or larger, the 31-gauge is noticeably gentler.

How much bacteriostatic water for 300 mcg doses?

Answer: 2 mL — 12 units per injection on a U-100 syringe.

A 1 mL reconstitution would require 6 units per dose; 3 mL would require 18 units (0.18 mL injection volume). The 2 mL middle ground keeps injection volumes modest while maintaining readable syringe markings. For subcutaneous research administration, volumes under 0.5 mL are standard per general injection-site tolerability principles.

Diluent choice: bacteriostatic water (0.9% benzyl alcohol as preservative, per USP <51>) is the standard for multi-dose reconstitution. Sterile water without preservative is single-use only — once punctured, it has no antimicrobial protection. The benzyl alcohol is what allows multiple draws from the same vial over days or weeks.

The 0.9% benzyl alcohol concentration is not arbitrary — it is the USP compendial standard for bacteriostatic water for injection. At this concentration, benzyl alcohol provides bacteriostatic activity against gram-positive organisms and limited activity against gram-negatives. It does not kill pre-existing contamination; it merely suppresses growth. That is why aseptic technique during reconstitution is non-negotiable. Swab the vial stopper with 70% isopropyl alcohol and let it dry for 30 seconds before puncturing. Alcohol that has not evaporated can be drawn into the vial with the needle, and residual isopropyl alcohol at the puncture site is a contamination vector, not a sterilizer.

Benzyl alcohol also has a practical limit: it degrades over time, and its antimicrobial efficacy declines after 28 days at refrigeration temperatures. This is precisely why USP <797> sets the 28-day beyond-use date for preservative-containing multidose vials. The peptide may remain chemically intact longer, but the preservative system is the limiting factor. After day 28, you are injecting into a solution with compromised antimicrobial defense — and the vial has been punctured dozens of times by then.

AOD 9604 vs. HGH Frag 176-191

| Property | AOD 9604 | HGH Frag 176-191 | |----------|----------|------------------| | Amino acid sequence | 177–191 + Tyr modification | 176–191 | | Length | 15 amino acids | 16 amino acids | | Molecular weight (approx.) | ~1813 Da | ~1913 Da | | Structural modification | Yes (Tyr substitution) | No (native sequence) | | Primary research focus | Lipid metabolism | Lipid metabolism |

AOD 9604 is a modified fragment of human growth hormone (amino acids 177–191 with a tyrosine substitution at the N-terminus). HGH Frag 176-191 is the unmodified 176–191 sequence. The single amino acid change is intended to improve stability and resistance to enzymatic degradation.

Practical difference for reconstitution: none. Both are lyophilized peptides, both reconstitute in bacteriostatic water, and both are dosed in the same microgram range. The molecular weight difference is negligible for dose calculations — you're dosing by mass, not molarity. The same 5 mg / 2 mL / U-100 syringe math applies unchanged.

The molarity distinction is worth spelling out. A 250 mcg dose of AOD 9604 (1813 Da) is approximately 0.138 micromoles. The same mass of HGH Frag 176-191 (1913 Da) is approximately 0.131 micromoles — a 5% difference. For receptor-binding studies where molar concentration matters, that 5% is real. For practical dosing, it is below the resolution of any syringe measurement you can make. If your research protocol specifies molar concentrations, calculate from the actual molecular weight on your certificate of analysis; if it specifies mass, the difference is irrelevant.

How does AOD 9604 differ from intact HGH?

Answer: AOD 9604 is a 15-amino-acid fragment of the HGH molecule (residues 177–191 with a tyrosine modification), while intact HGH is a 191-amino-acid single-chain polypeptide hormone. The fragment is designed to isolate lipolytic signaling from the broader somatotropic effects of full-length HGH.

The full HGH molecule binds the growth hormone receptor with two distinct binding sites, triggering dimerization and a cascade that includes lipolysis, IGF-1 release, and anabolic signaling. AOD 9604 retains only the C-terminal region — the portion associated with lipid mobilization — and omits the N-terminal receptor-binding domain responsible for the broader endocrine effects. This is a structural design principle, not a demonstrated clinical outcome. Researchers comparing the two should note that the fragment's receptor pharmacology is not identical to the parent hormone's, and the absence of IGF-1 stimulation is a hypothesis, not an established fact in the literature.

Reconstitution protocol

1. Draw 2 mL of bacteriostatic water into a 3 mL syringe
2. Inject slowly down the vial wall — not directly onto the lyophilized cake (direct impact causes foaming and peptide degradation)
3. Swirl gently to dissolve; do not vortex or shake vigorously (mechanical agitation can denature the tertiary structure)
4. Let the vial sit at room temperature for 5–10 minutes to ensure complete dissolution
5. Refrigerate at 2–8°C

Per USP <797>, a preservative-containing multidose vial is considered stable for 28 days after first puncture when stored under refrigeration. Discard after that window regardless of remaining volume.

The room-temperature dissolution step is often skipped, and it is a mistake. Lyophilized peptides dissolve faster at 20–25°C than at 2–8°C, and the 5–10 minute wait allows the solution to clarify fully. A faint opalescence immediately after swirling is normal — it is undissolved peptide in suspension. If the solution remains cloudy after 10 minutes, that is a red flag. It can indicate aggregation, incomplete lyophilization, or a compromised vial. Do not inject a cloudy peptide solution; the aggregate is not bioavailable and may trigger an immune response at the injection site.

Vortexing is the most common protocol violation. A vortex mixer generates shear forces that can unfold peptide tertiary structure, exposing hydrophobic residues that then aggregate irreversibly. The result is a solution that looks clear but contains soluble aggregates — invisible to the naked eye and undetectable without size-exclusion chromatography. Gentle swirling by hand for 30–60 seconds is sufficient for a 15-amino-acid peptide. If it has not dissolved after 60 seconds of swirling plus 10 minutes of rest, the problem is not insufficient agitation — it is a bad vial.

Storage and stability after reconstitution

Refrigeration at 2–8°C is the standard for reconstituted AOD 9604. Freezing is contraindicated — ice crystal formation can mechanically damage the peptide's tertiary structure and concentrate solutes in the remaining liquid, promoting aggregation. A reconstituted peptide that has been frozen should be discarded.

Light exposure is a secondary degradation vector. Peptide solutions are susceptible to photo-oxidation, particularly at aromatic residues. Store the vial in its original carton or an opaque container. The refrigerator door is the worst location — it experiences the widest temperature swings and the most light exposure every time the door opens. Store the vial on an interior shelf, not in the door.

The 28-day window from USP <797> is the conservative standard. Some peptide researchers extend this to 30 days based on their own stability testing, but the compendial standard exists because it is defensible. If your protocol runs longer than 28 days, reconstitute fresh vials rather than risking a compromised preparation. The cost of a second vial of bacteriostatic water is trivial compared to the cost of a contaminated study arm.

Where to source bacteriostatic water

• BAC Water Depot — multi-packs of 30 mL bacteriostatic water vials, USP-grade
• Amazon — convenience option; verify lot traceability and USP labeling before use

Where to source research peptides

• Alpha Amino USA — per-lot HPLC/MS COA, US-shipped
• PureRawz — broad peptide catalog with third-party testing
• Limitless Life Nootropics — research peptide supplier with published purity specs

For research use only — not clinical guidance.